Aprea Therapeutics, INC 8-K filings

Aprea Therapeutics has announced a private placement financing of up to $34 million to support its clinical development programs.

Aprea Therapeutics has updated its corporate presentation, highlighting progress in its clinical programs for ATR and WEE1 inhibitors and providing a financial overview.

Aprea Therapeutics reports a preliminary cash balance of approximately $21.6 million as of December 31, 2023, pending final audit.

Aprea Therapeutics has entered into an agreement to potentially sell up to $1 million of its common stock through an at-the-market offering.